Herantis Pharma and Nanoform Enter into Agreement for Proof of Concept Collaboration
Press Release Herantis Pharma Plc 9[th] February 2021 at 08:10 a.m. EET Herantis Pharma Plc (“Herantis”), an innovative clinical stage biotech company pioneering new disease modifying and regenerative biologic and gene therapies, today announced that they have entered into a Biologics Proof of Concept Agreement with Nanoform Finland Plc, an innovative nanoparticle medicine enabling company. The collaboration provides for formulation Proof of Concept studies (PoCs) to combine Herantis’ intranasally administered CDNF therapy for Parkinson’s disease, with Nanoform nanoparticle